Genprex Announces New Branding
AUSTIN, Texas, Sept. 6, 2011 /PRNewswire/ – Genprex, Inc., formerly known as Convergen LifeSciences, Inc., announced today that its first product candidate, the nanomolecular cancer therapy CNVN202, will be branded as Oncoprex(TM).
“We are establishing the Oncoprex brand in the oncology sector in recognition of our advancing development programs. We anticipate that when approved, Oncoprex will be used to unlock the unrealized potential of a growing list of cancer therapies that have limited application due to patients’ genomic profiles and drug resistance of targeted therapies and conventional chemotherapies,” stated Greg Heinlein, Chief Operating and Financial Officer.
Genprex controls a portfolio of biomedical technologies including targeted molecular therapeutics for cancer and other diseases. The novel technologies are protected by 14 issued and 10 pending patents. These broadly applicable technologies have been the subject of more than 20 peer-reviewed scientific publications in the fields of cancer, genomics and molecular biology.
Genprex is a clinical-stage biopharmaceutical company developing targeted molecular therapies for cancer. Its tumor suppression technologies work to induce apoptosis in cancer cells and to control cell signaling and inflammatory pathways to treat cancer at the molecular level without harming normal cells. The Company’s technologies were assembled from the fields of nanotechnology, genomic sciences, molecular medicine, advanced materials and manufacturing. Genprex is developing molecular therapies that target fundamental cancer pathways that are common to virtually all cancers, unlocking the unrealized potential of currently marketed cancer drugs.
The Company plans to use its nanomolecular therapies in combination with currently marketed agents to expand cancer patient populations for modern, targeted therapies as well as conventional chemotherapies. When combined with Genprex product candidates, researchers have shown that targeted therapies can become effective in non-targeted cancers by overcoming genomic limitations, and overcome drug resistance in targeted cancers. Genprex products also work synergistically major classes of traditional cancer chemotherapies to increase their cancer killing effectiveness.
Oncoprex is comprised of non-immunogenic lipid nanoparticles carrying the TUSC2 (FUS1) tumor suppressor to induce apoptosis (programmed cell death) and control inflammation and cell-signaling to kill cancer cells without harming normal cells. A phase II clinical trial is planned in early 2012 to evaluate Oncoprex in combination with TarcevaÂ® (erlotinib) in lung cancer patients without the EGFR mutation who would not be expected to benefit from erlotinib alone. For more information about Oncoprex and clinical trial information click here.
Contact:Greg Heinlein Phone: 512-597-5900 | Email: firstname.lastname@example.org Genprex, Inc. - www.genprex.com
SOURCE Genprex, Inc.